RxDoctor Payments Data

Christopher Rash, MD

Cardiovascular Disease · Rockingham, VANPI 1457568735

Payments from drug & device makers

$182in general payments, 2019–2025

Across 8 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$61
  • Edwards Lifesciences$57
  • AstraZeneca$28
  • Regeneron Healthcare Solutions, Inc.$25
  • Irhythm Technologies, Inc.$12

What the payments were for

  • Food & beverage$12971%
  • Education$5329%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$182 in reported general payments places this provider in the 15th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$185,771
Medicare patients
1,672
Services billed
3,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban336$415,752
EntrestoSacubitril/Valsartan126$149,720
FarxigaDapagliflozin Propanediol111$121,502
JardianceEmpagliflozin81$109,790
Repatha SureclickEvolocumab118$104,712
XareltoRivaroxaban89$92,115
Praluent PenAlirocumab21$22,595
Dabigatran EtexilateDabigatran Etexilate Mesylate17$7,205
Metoprolol Succinate357$4,954
Ezetimibe190$4,741
Rosuvastatin Calcium311$4,218
Amiodarone Hcl43$2,969
Atorvastatin Calcium247$2,510
Losartan Potassium272$2,180
Bumetanide57$2,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$28$121,502111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Rockingham

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →